Icotrokinra, also known as JNJ-77242113, is an oral interleukin (IL)-23 receptor antagonist that is being evaluated for moderate to severe psoriasis in phase 3 trials. “One caveat,” Strober ...

A doctor may prescribe injectable treatments, such as methotrexate, TNF-alpha inhibitors, or interleukin inhibitors, for moderate to severe psoriasis when other treatments don’t work.

It can be difficult to tell the difference between seborrheic dermatitis vs. psoriasis when symptoms appear only on the scalp. Both conditions can cause scaly, red patches, but the specific appearance ...

Please provide your email address to receive an email when new articles are posted on . The proportion of deucravacitinib-treated patients that reported no quality-of-life impact increased from 0% ...

SCALP psoriasis, characterised by erythemato-squamous plaques extending beyond the hairline, remains a challenging dermatological condition. Symptoms such as itching, hair loss, and visible lesions ...

Otezla also led to significant reductions in secondary measures like whole body itch and scalp PGA compared ... top-line results in moderate to severe genital psoriasis, which affects around ...

Jan. 20, 2025 — People with the skin condition psoriasis often have invisible inflammation in the small intestine with an increased propensity for 'leaky gut', according to new research.

The following is a summary of “A year in review: new treatments and expanded indications in dermatology in 2024,” published in the January 2025 issue of Dermatology by McGrath et al. In 2024, ...